tepoditamab   Click here for help

GtoPdb Ligand ID: 10353

Synonyms: MCLA-117 | MCLA117 | PB9122
Immunopharmacology Ligand
Compound class: Antibody
Comment: Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds CLEC12A on myeloid cells and CD3ε on cytotoxic T cells. It is being developed by Merus as a novel therapy for acute myeloid leukemia (AML) [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Immunopharmacology Comments
CLEC12A is a myeloid differentiation antigen. It is expressed on 90-95% of newly diagnosed and relapsed AML, and is selectively expressed on leukemic stem cells but not on normal early hematopoietic progenitors. Targeting CLEC12A and CD3ε simultaneously with MCLA-117 is expected to kill both AML leukemic blasts and AML leukemic stem cells, including residual leukemic stem cells in bone marrow niche compartments [1].